
|Videos|July 13, 2020
Radioiodine Refractory Differentiated Thyroid Carcinoma
Author(s)Targeted Oncology
A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
3
VA Study Finds Potential OS Benefit for Enzalutamide in Older mCSPC Patients
4
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
5





























